| John P Luckett Iii, MD | |
|
700 18th St S Ste 601, Birmingham, AL 35233-3800 | |
| (205) 325-8507 | |
| Not Available |
| Full Name | John P Luckett Iii |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 6 Years |
| Location | 700 18th St S Ste 601, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336646652 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Callahan Eye Hospital | Birmingham, AL | Hospital |
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alabama Ophthalmology Associates, P.c. | 5193616035 | 7 |
| Uab Callahan Eye Hospital Authority | 1557516895 | 45 |
News Archive
Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.
Patients who are bedridden or unable to move their legs are often at risk of developing Deep Vein Thrombosis (DVT), a potentially life-threatening condition caused by blood clots forming along the lower extremity veins of the legs. A team of researchers from the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Engineering has invented a novel sock that can help prevent DVT and improve survival rates of patients.
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.
CoActiv Medical debuts at the 2013 Radiological Society of North America conference EXAM-PACS version 3.0. CoActiv leverages its longstanding experience with standards-based technology to bring new market-leading features and functionality to its flagship enterprise PACS and to provide more options and flexibility across the entire product line with expanded deployment options and a more robust vendor neutral archive.
› Verified 3 days ago
| Entity Name | Alabama Ophthalmology Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366484941 PECOS PAC ID: 5193616035 Enrollment ID: O20040322000994 |
News Archive
Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.
Patients who are bedridden or unable to move their legs are often at risk of developing Deep Vein Thrombosis (DVT), a potentially life-threatening condition caused by blood clots forming along the lower extremity veins of the legs. A team of researchers from the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Engineering has invented a novel sock that can help prevent DVT and improve survival rates of patients.
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.
CoActiv Medical debuts at the 2013 Radiological Society of North America conference EXAM-PACS version 3.0. CoActiv leverages its longstanding experience with standards-based technology to bring new market-leading features and functionality to its flagship enterprise PACS and to provide more options and flexibility across the entire product line with expanded deployment options and a more robust vendor neutral archive.
› Verified 3 days ago
| Entity Name | Uab Callahan Eye Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023358850 PECOS PAC ID: 1557516895 Enrollment ID: O20130312000475 |
News Archive
Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.
Patients who are bedridden or unable to move their legs are often at risk of developing Deep Vein Thrombosis (DVT), a potentially life-threatening condition caused by blood clots forming along the lower extremity veins of the legs. A team of researchers from the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Engineering has invented a novel sock that can help prevent DVT and improve survival rates of patients.
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.
CoActiv Medical debuts at the 2013 Radiological Society of North America conference EXAM-PACS version 3.0. CoActiv leverages its longstanding experience with standards-based technology to bring new market-leading features and functionality to its flagship enterprise PACS and to provide more options and flexibility across the entire product line with expanded deployment options and a more robust vendor neutral archive.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John P Luckett Iii, MD 1000 19th St S, Birmingham, AL 35205-4804 Ph: (205) 930-0700 | John P Luckett Iii, MD 700 18th St S Ste 601, Birmingham, AL 35233-3800 Ph: (205) 325-8507 |
News Archive
Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.
Patients who are bedridden or unable to move their legs are often at risk of developing Deep Vein Thrombosis (DVT), a potentially life-threatening condition caused by blood clots forming along the lower extremity veins of the legs. A team of researchers from the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Engineering has invented a novel sock that can help prevent DVT and improve survival rates of patients.
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.
CoActiv Medical debuts at the 2013 Radiological Society of North America conference EXAM-PACS version 3.0. CoActiv leverages its longstanding experience with standards-based technology to bring new market-leading features and functionality to its flagship enterprise PACS and to provide more options and flexibility across the entire product line with expanded deployment options and a more robust vendor neutral archive.
› Verified 3 days ago
Carol E Rosenstiel, OD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 200, Birmingham, AL 35233 Phone: 205-325-8620 | |
Alex J Wright, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1720 University Blvd, Birmingham, AL 35233 Phone: 205-325-8100 Fax: 205-325-8547 | |
Elmar M Lawaczeck, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1009 Montgomery Hwy, Suite 200, Birmingham, AL 35216 Phone: 205-397-9400 Fax: 205-397-9455 | |
Matthew Henry Oltmanns, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2208 University Blvd Ste 101, Birmingham, AL 35233 Phone: 205-933-2625 Fax: 205-558-2553 | |
Harold Augustus Helms, MD, PHD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1100 23rd St S, Ste 100, Birmingham, AL 35205 Phone: 205-933-2020 Fax: 205-933-0908 | |
Krupa Hasmukh Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-325-8620 | |
William Charles Gambla, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-996-8660 |